Clinical trials: Diabetic Mellitus
Diabetes, Hypoglycemia
Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus
The purpose of this study is to determine the safety of BHT-3021 injections given weekly for 12 weeks and to evaluate the effect of BHT-3021 on antibody and immune (T cell) responses to autoantigens (e.g. insulin).
- Trial name
- NCT00453375
- Testing
- BHT-3021
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 80 people
- Sponsor
- Bayhill Therapeutics
Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.
- Trial name
- GLOW2 (NCT06270836)
- Testing
- Tarcocimab
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 255 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Kidney Disease
Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients
The study intends to investigate the personal experiences of diabetic kidney disease patients who take part in a separate clinical study including a specific medication intervention.
- Trial name
- NCT06101901
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Diabetic Foot Ulcer
Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers
This study aims to compare two treatment approaches for diabetic foot ulcers (DFUs): the standard of care (SOC) alone versus SOC combined with OCM.
- Trial name
- NCT07161830
- Testing
- Omeza® Complete Matrix, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 180 people
- Sponsor
- Omeza, LLC
Diabetes Mellitus Type 2, Hypertension
MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)
The purpose of this study is to determine whether MC-1 alone and in combination with an ACE inhibitor is effective in reducing blood pressure and metabolic dysfunctions associated with diabetes
- Conditions
- Diabetes Mellitus Type 2, Hypertension, Metabolic Syndrome
- Trial name
- NCT00157729
- Testing
- pyridoxal-5'-phosphate with and without ACE inhibitor
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Medicure
Diabetes Mellitus, Type 2
Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
Primary Objective: -To assess the change in glycosylated hemoglobin (HbA1c) in uncontrolled Type 2 diabetes patients on OAD agent in Jordan after 6 months of treatment with basal insulin (Insulin glargine).
- Trial name
- NEWLAN (NCT02606357)
- Testing
- INSULIN GLARGINE
- Where
- Jordan
- Volunteers
- 242 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial investigate the the long-term safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- NCT01704378
- Testing
- biphasic insulin aspart
- Where
- 17 sites in Finland, Norway and 2 more
- Volunteers
- 89 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Special Survey for Type 1 or Type 2 Diabetic Patients
This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia episodes under normal clinical practice for patients with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01487408
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 1,463 people
- Sponsor
- Novo Nordisk A/S
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Diabetes (DM)
A Study to Investigate a Transdermal Continuous Glucose Monitoring System in Diabetic Patients for a Period of 28 Days
Single-centre, open label (unblinded). A maximum of 48 patients will be enrolled in 4 Cohorts of 10 patients and 2 potential replacements each. Diabetic patients (type 1 and 2).
- Trial name
- FiberSense (NCT06868043)
- Testing
- FiberSense System
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- EyeSense GmbH
Diabetic Foot Ulcer
Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers
Clinical Trial Phase III-b Study Sponsor: European Egyptian Pharmaceutical Industries Sample Size: 120 patients (60 per arm) Study Population: Patients with Diabetic foot ulcer of any stage after proper surgical treatment - if…
- Trial name
- PED111 (NCT01531517)
- Testing
- Royal Jelly and Panthenol (PedyPhar® Ointment), Panthenol Ointment
- Where
- 2 sites in Egypt
- Volunteers
- 47 people
- Sponsor
- European Egyptian Pharmaceutical Industries
Diabetes Mellitus, Type 2
Glufast On Insulin Glargine Trial in Type 2 DM
We will evaluate the efficacy and safety of combination therapy of 10 mg mitiglinide or 0.2mg voglibose with insulin glargine for 16 weeks after single administration of insulin glargine for 4 weeks in type 2 diabetic patients…
- Trial name
- GLORIA (NCT00663884)
- Testing
- Mitiglinide, Voglibose
- Where
- South Korea
- Volunteers
- 167 people
- Sponsor
- JW Pharmaceutical
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Local Registration Trial in China Humalog Mix 50
The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in insulin-requiring diabetic patients treated twice daily with human insulin mix 50/50, versus the 2-hour PPBG excursion…
- Trial name
- NCT00191581
- Testing
- Humalog Mix 50, Human Insulin Mix 50:50
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Obesity
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.
- Trial name
- NCT00478322
- Testing
- INCB013739
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071975
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Diabetic Neuropathies
ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy
To demonstrate the superiority of ASP8825 over placebo and dose response in patients with painful diabetic polyneuropathy.
- Trial name
- NCT00508430
- Testing
- ASP8825
- Where
- 8 sites in Japan
- Volunteers
- 199 people
- Sponsor
- Astellas Pharma Inc
Diabetic Foot Ulcer, Ulcer Foot
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available treatments for diabetic foot wounds.
- Conditions
- Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
- Trial name
- NCT06403605
- Testing
- Mirragen Advanced Wound Matrix, Fibracol
- Where
- 15 sites in United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- ETS Wound Care, LLC
Peripheral Arterial Disease, Diabetic Foot
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety of intramuscular administration of human placenta-derived cells (PDA-002) in subjects with…
- Trial name
- DFU-002 (NCT02264288)
- Testing
- PDA-002
- Where
- 45 sites in United States
- Volunteers
- 159 people
- Sponsor
- Celularity Incorporated
Diabetic Macular Edema, Diabetic Retinopathy
4D-150 in Patients With Diabetic Macular Edema
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
- Trial name
- NCT05930561
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- 4D Molecular Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.